Cargando…

Molecular Farming of Pembrolizumab and Nivolumab

Immune checkpoint inhibitors (ICIs) are a class of immunotherapy agents capable of alleviating the immunosuppressive effects exerted by tumorigenic cells. The programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint is one of the most ubiquitous checkpoints utilized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stark, Michael C., Joubert, Anna M., Visagie, Michelle H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298108/ https://www.ncbi.nlm.nih.gov/pubmed/37373192 http://dx.doi.org/10.3390/ijms241210045

Ejemplares similares

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Efficacy of Pembrolizumab and Nivolumab in Crossing the Blood Brain Barrier
por: Abid, Haisam, et al.
Publicado: (2019)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
por: Fessas, Petros, et al.
Publicado: (2017)

In vitro effects of 2-methoxyestradiol-bis-sulphamate on reactive oxygen species and possible apoptosis induction in a breast adenocarcinoma cell line
por: Visagie, Michelle H, et al.
Publicado: (2011)

2-Methoxyestradiol-bis-sulphamate refrains from inducing apoptosis and autophagy in a non-tumorigenic breast cell line
por: Visagie, Michelle H, et al.
Publicado: (2012)

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
por: Cui, Pengfei, et al.
Publicado: (2020)

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
por: Ksienski, Doran, et al.
Publicado: (2021)

Crosstalk between the Warburg effect, redox regulation and autophagy induction in tumourigenesis
por: Gwangwa, Mokgadi Violet, et al.
Publicado: (2018)

The Biological Relevance of Papaverine in Cancer Cells
por: Gomes, Daniella Anthea, et al.
Publicado: (2022)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Sulphamoylated Estradiol Analogue Induces Reactive Oxygen Species Generation to Exert Its Antiproliferative Activity in Breast Cancer Cell Lines
por: Lebelo, Maphuti T., et al.
Publicado: (2020)

Dysregulation of Catalase by a Sulphamoylated Estradiol Analogue Culminates in Antimitotic Activity and Cell Death Induction in Breast Cancer Cell Lines
por: Lebelo, Maphuti T., et al.
Publicado: (2021)

Sulphamoylated estradiol analogue induces antiproliferative activity and apoptosis in breast cell lines
por: Visagie, Michelle, et al.
Publicado: (2012)

The in vitro effects of 2-methoxyestradiol-bis-sulphamate on cell numbers, membrane integrity and cell morphology, and the possible induction of apoptosis and autophagy in a non-tumorigenic breast epithelial cell line
por: Visagie, Michelle H., et al.
Publicado: (2010)

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes
por: Wells, Leah, et al.
Publicado: (2022)

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
por: Lepir, Tanja, et al.
Publicado: (2019)

Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center
por: Hall, Evan, et al.
Publicado: (2020)

RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment
por: Siddiqui, Jalal, et al.
Publicado: (2021)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

In Vitro Effects of Papaverine on Cell Proliferation, Reactive Oxygen Species, and Cell Cycle Progression in Cancer Cells
por: Gomes, Daniella A., et al.
Publicado: (2021)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center
por: Vo, Henry Hiep, et al.
Publicado: (2022)

Antimitotic drugs in the treatment of cancer
por: van Vuuren, Rustelle Janse, et al.
Publicado: (2015)

A 2-methoxyestradiol bis-sulphamoylated derivative induces apoptosis in breast cell lines
por: Visagie, Michelle Helen, et al.
Publicado: (2015)

In vitro assessment of a computer-designed potential anticancer agent in cervical cancer cells
por: Visagie, Michelle Helen, et al.
Publicado: (2016)

Effects of glutamine deprivation on oxidative stress and cell survival in breast cell lines
por: Gwangwa, Mokgadi Violet, et al.
Publicado: (2019)

In Vitro Effects of Papaverine on Cell Migration and Vascular Endothelial Growth Factor in Cancer Cell Lines
por: Gomes, Daniella Anthea, et al.
Publicado: (2022)

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
por: Laliberté, François, et al.
Publicado: (2020)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

A bis-sulphamoylated estradiol derivative induces ROS-dependent cell cycle abnormalities and subsequent apoptosis
por: Visagie, Michelle Helen, et al.
Publicado: (2017)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
por: Cortellini, Alessio, et al.
Publicado: (2018)

Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis
por: Ndjana Lessomo, Fabrice Yves, et al.
Publicado: (2023)

Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors
por: Nomura, Motoo, et al.
Publicado: (2020)

Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Small Cell Lung Cancer by Platelet-Derived Microparticles in Circulating Blood
por: Liu, Tingting, et al.
Publicado: (2021)

Genetic Containment for Molecular Farming
por: Klocko, Amy L.
Publicado: (2022)

Plant molecular farming: systems and products
por: Horn, M. E., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_n97dgk8vcscr8hkt749o7dal7l